FORM8-K HILLENBRAND,INC.

Similar documents
FORM8-K HILLENBRAND,INC.

DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12

WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

HILLENBRAND INDUSTRIES INC

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Capital Senior Living Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

WALGREENS BOOTS ALLIANCE, INC.

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

RULES OF CONDUCT OF INSIDERS RESPECTING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

WASHINGTON,D.C FORM8-K. CurrentReport PursuanttoSection13or15(d)ofthe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K

Tamsulosin Hydrochloride 0.4 mg Capsule

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

PRICE DEMERS & CO. Barristers, Solicitors & Notaries Public

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Oragenics, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL

MDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46

Employment Contract. This sample employment contract is from Self-Employment vs. Employment Status, CDHA (no date available)

Do not edit or delete any questions from this application. Doing so will result in immediate disqualification of your request.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Neuralstem, Inc. (Exact name of registrant as specified in Charter)

The Dental Corporation Opportunity

CytoDyn Inc. (Exact name of registrant as specified in its charter)

DARA Reports Year-End 2012 Financial Results

Teaming Agreement. Grant of Charter and License. Dues. Name and Logo. Mission Commitment. Chapter Standards Compliance.

AFFIN HOLDINGS BERHAD (Company No.: W) (Incorporated in Malaysia under the Companies Act, 2016) NOTICE TO SHAREHOLDERS IN RELATION TO THE

For personal use only

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT

For personal use only

January 30, 2018 Dow Wilson President and Chief Executive Officer

New Markets Tax Credit CDE Certification Question & Answer

Assembly Bill No. 200 Committee on Health and Human Services

Investor Presentation

DELTA DENTAL PREMIER

INFINITY PHARMACEUTICALS, INC.

Please find enclosed Dosimetry Service Licence No which replaces Dosimetry Service Licence No

Constitution for the National Association to Advance Fat Acceptance, Inc. PREAMBLE

PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS. LCB File No. R July 6, 2001

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

2016 Grant Application Form

USE OF ALCOHOLIC BEVERAGES ON CAMPUS GUIDELINES

DW PENNICHUCK EAST UTILITY, INC. Petition for Franchise Approval and Rates. Order Nisi Approving Franchise and Rate Petition

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

Consultancy Support Services for the Procurement of LEU for the establishment of the IAEA LEU Bank

Integrity Applications, Inc. (Exact Name of Registrant as Specified in Its Charter)

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

DISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Forward-Looking Statements

ClearWay Minnesota SM. Release Request for Qualifications. Demonstrating the Impact of Menthol Policies on Youth

FIRSTQUARTER2018 RESULTSPRESENTATION

Washington,D.C FORM8-K. NovoCureLimited. (Exactnameofregistrantasspecifiedinitscharter) Jersey (StateorOtherJurisdiction

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

No Stomach For Cancer

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CSA Briefing Note Regarding Joint Application against the University and Re-Commencing Collection of CFS/CFS-O Fees

RESOLUTION NO A RESOLUTION APPROVING REFERAL TO THE ELECTORS OF THE CITY OF ALBANY THE

NOTICE TO BIDDERS: HONDA PIPELINE PHASE 1, Owner: THE WATER WORKS AND SEWER BOARD OF THE CITY OF ANNISTON, CALHOUN COUNTY, ALABAMA.

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

ITAMAR MEDICAL LTD. (Name of registrant)

(Tentative Translation)

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

City of Carson 701 E. Carson St., Carson, CA Telephone: (310) ; ci.carson.ca.us

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

BVI Limited Partnership Hedge Funds: Calling Japan

Align your brand with one of education s most highly respected and experienced organizations.

Genomic Health. Kim Popovits, Chairman, CEO and President

Re: Bayer s false and deceptive marketing for its Men s Multis for prevention of cancer

Fiscal 2019 Annual Meeting of Shareholders December 18, Presentation by Lori Woods, Chief Executive Officer

Regulations. On Proper Conduct in Research TEL AVIV UNIVERSITY

For personal use only

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

INVESTOR PRESENTATION

QUESTIONNAIRE ANTI MONEY LAUNDERING (Including Counter Terrorist Financing, Financial Sanctions Monitoring, KYC)

Standards of Conduct for Transmission Providers

Building a Fully Integrated Biopharmaceutical Company. June 2014

The Saskatchewan Gazette

Tea Party or Luncheon Bake Sales. Walk-a-thon, Dance-a-thon, etc. Black-Tie Event

Transcription:

UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): February1,2016 HILLENBRAND,INC. (Exact Name of Registrant as Specified in Charter) Indiana 1-33794 26-1342272 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.) Incorporation) OneBatesvilleBoulevard Batesville,Indiana 47006 (Address of Principal Executive Office) (Zip Code) Registrant s telephone number, including area code: (812)934-7500 NotApplicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o o o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item8.01OtherEvents. On February 1, 2016, Hillenbrand, Inc. ( Hillenbrand ) completed its acquisition of Red Valve Company, Inc. ( Red Valve ) and certain real estate used by Red Valve from Corinthian Realty, L.L.C. Attached as Exhibit 99.1 hereto is a copy of the press release issued by Hillenbrand regarding the completion of this acquisition. Additional information regarding Hillenbrand s acquisition of Red Valve was previously disclosed in Item 8.01 of Hillenbrand s Current Report on Form 8-K filed on December 22, 2015. The information furnished pursuant to Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ( Exchange Act ), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any Hillenbrand filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item9.01FinancialStatementsandExhibits. (d) Exhibits. ExhibitNumber Description 99.1 Press Release, dated February 2, 2016, of Hillenbrand, Inc. 1

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DATE: February 2, 2016 HILLENBRAND,INC. BY: /S/ Nicholas R. Farrell Nicholas R. Farrell Vice President, General Counsel & Secretary 2

EXHIBITINDEX ExhibitNumber Description 99.1 Press Release, dated February 2, 2016, of Hillenbrand, Inc. 3

Exhibit99.1 HillenbrandCompletesAcquisitionofRedValve BATESVILLE,Ind.,Feb.2,2016 /PR Newswire / Hillenbrand, Inc. (NYSE: HI) has completed its previously announced acquisition of Red Valve Company, Inc. for a purchase price of $131.9 million in cash, including $3.3 million for related real estate. Based in Carnegie, Pa., Red Valve is a global leader in highly-engineered valves designed to operate in the harshest municipal and industrial wastewater environments. Its products support mission critical applications in water, power and mining and other general industrial markets. Red Valve joins Hillenbrand s Process Equipment Group, which includes ABEL, a globally-recognized leader in positive displacement pumps. This acquisition advances Hillenbrand s strategy to transform into a world-class global diversified industrial company. Red Valve complements Hillenbrand s recent ABEL acquisition, increasing the company s ability to expand into new end markets and geographies that have solid profitable growth potential within the flow control space. AboutHillenbrand Hillenbrand (www.hillenbrand.com) is a global diversified industrial company with multiple market-leading brands that serve a wide variety of industries across the globe. We pursue profitable growth and robust cash generation in order to drive increased value for our shareholders. Hillenbrand s portfolio is composed of two business segments: the Process Equipment Group and Batesville. The Process Equipment Group businesses design, develop, manufacture and service highly engineered industrial equipment around the world. Batesville is a recognized leader in the North American death care industry. Hillenbrand is publicly traded on the NYSE under HI. AboutRedValve Red Valve Company (www.redvalve.com) is the world s largest manufacturer of pinch valves and has an international reputation for quality-engineered valves designed for long life in the toughest municipal and industrial applications. Red Valve advanced elastomer technology is engineered into every Red Valve pinch valve, control valve, slurry knife gate valve, pressure sensor, Redflex Expansion Joint and revolutionary all-rubber Tideflex Check Valve. CONTACTS CorporateCommunicationsforHillenbrand Tory Flynn, Director, Corporate Communications Phone: 812-931-5024 E-mail: tory.flynn@hillenbrand.com InvestorRelationsforHillenbrand Chris Gordon, Director, Investor Relations

Phone: 812-931-5001 E-mail: chris.gordon@hillenbrand.com